White Lighthouse Investment Management Inc. Sells 118 Shares of Johnson & Johnson $JNJ

White Lighthouse Investment Management Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ) by 1.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,812 shares of the company’s stock after selling 118 shares during the quarter. White Lighthouse Investment Management Inc.’s holdings in Johnson & Johnson were worth $1,040,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in JNJ. Brighton Jones LLC lifted its position in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Wealth Group Ltd. bought a new stake in Johnson & Johnson in the 1st quarter valued at $218,000. GAMMA Investing LLC lifted its position in Johnson & Johnson by 48.0% during the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock worth $7,215,000 after buying an additional 14,118 shares in the last quarter. Keudell Morrison Wealth Management lifted its position in Johnson & Johnson by 0.7% during the 1st quarter. Keudell Morrison Wealth Management now owns 10,781 shares of the company’s stock worth $1,788,000 after buying an additional 76 shares in the last quarter. Finally, LaFleur & Godfrey LLC lifted its position in Johnson & Johnson by 6.9% during the 1st quarter. LaFleur & Godfrey LLC now owns 138,853 shares of the company’s stock worth $23,027,000 after buying an additional 8,964 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.3%

Shares of JNJ opened at $192.31 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market cap of $463.15 billion, a P/E ratio of 18.56, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48. The firm’s 50-day simple moving average is $181.99 and its 200 day simple moving average is $165.84.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

Analysts Set New Price Targets

JNJ has been the topic of several analyst reports. Morgan Stanley set a $190.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday. Sanford C. Bernstein boosted their price target on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Raymond James Financial boosted their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. Finally, Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a research report on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.